Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) is a Nasdaq-listed company focused on ionization-based weather modification technology, including rainfall generation, snow enhancement, and fog mitigation. The RAIN news feed on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures that explain how its Weather Enhancement Technology Array (WETA) platform is being tested, deployed, and evaluated.
Investors and observers following RAIN news can expect coverage of technology trials and field results, such as reports on precipitation enhancement in international locations and early indications from U.S. installations. The company’s releases discuss peer-reviewed findings that its ionization rainfall generation systems have produced statistically significant rainfall increases in randomized trials, and they provide narrative detail on how installations are designed to influence rainfall and snowpack in water-stressed regions.
RAIN news also highlights corporate and governance developments, including appointments to the board of directors and the addition of strategic and technical advisors with backgrounds in weather modification, atmospheric science, quantum physics, and corporate governance. These items provide context on how the company is building scientific and leadership capacity as it pursues commercialization of its WETA platform.
Regulatory and listing-related updates form another important category of RAIN news. The company has issued press releases and filed Form 8-K reports describing its interactions with The Nasdaq Stock Market LLC, including prior notices about continued listing standards and subsequent confirmation that its securities are listed on the Nasdaq Capital Market under the symbols RAIN and RAINW. By reviewing this news stream, readers can track both operational progress in weather enhancement projects and key corporate milestones.
Rain Therapeutics Inc. (NASDAQ: RAIN) will announce its Q2 financial results on August 4, 2022, at 2:00 PM PT. The company is focused on precision oncology therapeutics, particularly its lead candidate, milademetan, which targets oncogenic drivers. The announcement will include a conference call to discuss financial results and recent progress. Investors can access a replay via the company’s website afterwards. Rain Therapeutics is committed to genetically selecting patients for its therapies, enhancing treatment specificity in cancer care.
Rain Therapeutics (NasdaqGS: RAIN) announced three poster presentations at the 2022 ASCO Annual Meeting, focusing on their oral MDM2 inhibitor, milademetan. The presentations will cover:
- Using CDKN2A loss to predict sensitivity (Abstract 3136)
- MANTRA: A phase 3 study of milademetan vs. trabectedin in dedifferentiated liposarcomas (Abstract TPS11589)
- MANTRA-2: A phase 2 study in TP53-wild type tumors (Abstract TPS3165)
All posters will be available on the Rain website following the event.
Rain Therapeutics Inc. (NASDAQ: RAIN) announced its Q1 2022 results, reporting a net loss of $17.4 million compared to $6.8 million in the same quarter last year. The company has a cash position of $123.2 million, providing a runway into the first half of 2024 for its clinical programs. Key updates include earlier-than-expected topline data from the Phase 3 MANTRA trial for liposarcoma slated for H1 2023 and planned commencement of Phase 2 trials MANTRA-3 and MANTRA-4 in Q4 2022. Research and development expenses rose to $13.6 million, largely due to ongoing trials.
Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to report its financial results for Q1 2022, ending March 31, on May 4, 2022. The announcement highlights the company’s progress in precision oncology. Following the report, a conference call will take place at 2:00 PM PT (5:00 PM ET) to discuss business performance. Rain specializes in developing therapies targeting oncogenic drivers, including its lead candidate, milademetan, an oral MDM2 inhibitor. This precision approach aims to select patients based on tumor genetics.
Rain Therapeutics Inc. (NASDAQ: RAIN) will present a poster and two trials at the AACR Annual Meeting 2022 from April 8-13. The poster, titled Exploration of MDM2 gene amplification, emphasizes the prognosis in solid tumors and will be presented by Dr. Vijaya Tirunagaru on April 11. The ongoing trials include a phase 2 study of the MDM2 inhibitor milademetan and a phase 3 trial comparing it against trabectedin in liposarcomas. These presentations highlight Rain's focus on precision oncology and genetic patient selection for better therapeutic outcomes.
Rain Therapeutics reported a net loss of $18.0 million for Q4 2021, leading to a total annual loss of $51.4 million. Despite this, the company maintains a strong cash position of $140.2 million, expected to fund ongoing clinical trials, including a pivotal Phase 3 trial for milademetan in liposarcoma. Both MANTRA and MANTRA-2 trials are progressing on schedule, with all site activations anticipated by Q1 2022. Rain has also entered a supply agreement with Roche for atezolizumab, supporting a Phase 1 combination trial set for later in 2022.
Rain Therapeutics Inc. (NasdaqGS: RAIN) will report its financial results for Q4 and the full year ended December 31, 2021, on March 3, 2022. The late-stage precision oncology firm focuses on developing therapies targeting oncogenic drivers. A conference call will be held on the same day at 1:30 pm PT (4:30 pm ET) to discuss business and financial results. Rain’s lead product, milademetan, is an oral MDM2 inhibitor, and the company is also working on a preclinical program targeting RAD52.
Rain Therapeutics has expanded its leadership team with experienced professionals from notable firms such as Loxo/Lilly, Gilead, Seagen, and AltruBio. Key new appointments include Nora Ku as VP of Clinical Development, Buenaflor Nicolas as VP of Global Drug Safety, Tina Kim-Hafken as VP of Regulatory Affairs, and Steve Flint as VP of People & Culture. Additionally, John Maraganore continues as a Special Advisor since March 2021. These strategic hires aim to enhance Rain’s late-stage clinical and regulatory operations as they develop innovative cancer therapies, particularly the oral inhibitor milademetan.
Rain Therapeutics Inc. (NASDAQ: RAIN) will present a corporate overview at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 pm ET. CEO Avanish Vellanki will lead the presentation, followed by a Q&A session. The presentation will be available for replay on the Rain website for 30 days post-event. Rain specializes in precision oncology, targeting oncogenic drivers and selecting patients based on genetic profiles, with its lead candidate being milademetan, an MDM2 inhibitor effective in various cancers.
Rain Therapeutics Inc. (NASDAQ: RAIN) will participate in two upcoming virtual events. CEO Avanish Vellanki will present at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 3:30 pm ET. Additionally, Rain will be featured in a virtual fireside chat at the Guggenheim Oncology Conference on February 10, 2022, at 4:00 pm ET. Both events will provide insights into the company's precision oncology therapies, including their leading candidate, milademetan. Replays of these presentations will be available on Rain’s official website for 30 days post-event.